Summer Private Company Showcase 2020

10 August 2020

AUM Biosciences will be presenting its oncology pipeline at the Capital 2020 Virtual Investor Conference. This event brings together companies from a range of sectors including healthcare, AI and deep technologies, and many more. AUM Biosciences to Present at the Upcoming 2020 Summer Private Company Showcase

AUM Biosciences, a clinical-stage biopharmaceutical company aiming to democratize R&D with a focus on discovering, acquiring, and developing novel therapeutics in oncology, is pleased to announce that Vishal Doshi, CEO, will be presenting an overview of the company at the Summer Private Company Showcase 2020 hosted by Solebury Trout, Piper Sandler and White & Case on Monday, August 10th at 9 A.M. Eastern Time.

To access the presentation, please log in HERE

About AUM Biosciences

AUM Biosciences is an award-winning, oncology-focused biotechnology company that aims to accelerate the development of innovative, affordable cancer medicines for patients in Asia and around the world. AUM Biosciences focuses on early-stage development of innovative medicines for the treatment of Asian-prevalent cancers.

The company holds exclusive worldwide rights in all disease indications for 2 first-in-class technologies with a strong composition of matter patents in all major territories. 1) MNK Inhibition and 2) Multi-Kinase Inhibition (PIM/PI3K/mTOR). AUM’s most advanced program is Phase II ready in colorectal cancer, and 2 additional pre-clinical programs have clear pathways to orphan drug designation. For 2 years in a row, the company has been awarded the Frost & Sullivan Asia-Pacific Biotech Entrepreneurial Company of the Year Award.

For more information, please visit www.aumbiosciences.com

Investor Relations Contact:

Mr. Terig Hughes

Chief Financial Officer

Investors@aumbiosciences.com